Privia Health Group Inc’s filing revealed that its Chief Executive Officer Mehrotra Parth unloaded Company’s shares for reported $0.39 million on May 13 ’25. In the deal valued at $24.52 per share,15,909 shares were sold. As a result of this transaction, Mehrotra Parth now holds 407,234 shares worth roughly $9.32 million.
Then, Mehrotra Parth sold 13,773 shares, generating $344,187 in total proceeds. Upon selling the shares at $24.99, the Chief Executive Officer now owns 423,143 shares.
Before that, Mountcastle David sold 3,322 shares. Privia Health Group Inc shares valued at $83,017 were divested by the EVP & Chief Financial Officer at a price of $24.99 per share. As a result of the transaction, Mountcastle David now holds 172,909 shares, worth roughly $3.96 million.
Needham initiated its Privia Health Group Inc [PRVA] rating to a Buy in a research note published on January 10, 2025; the price target was $25. A number of analysts have revised their coverage, including Macquarie’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. KeyBanc Capital Markets began covering PRVA with “an Overweight” recommendation on October 11, 2024. Robert W. Baird started covering the stock on May 30, 2024. It rated PRVA as “an Outperform”.
Price Performance Review of PRVA
On Monday, Privia Health Group Inc [NASDAQ:PRVA] saw its stock jump 1.06% to $22.89. Over the last five days, the stock has lost -1.51%. Privia Health Group Inc shares have risen nearly 17.08% since the year began. Nevertheless, the stocks have risen 30.80% over the past one year. While a 52-week high of $26.09 was reached on 05/08/25, a 52-week low of $16.37 was recorded on 01/02/25.
Levels Of Support And Resistance For PRVA Stock
The 24-hour chart illustrates a support level at 22.64, which if violated will result in even more drops to 22.39. On the upside, there is a resistance level at 23.21. A further resistance level may holdings at 23.53.
The most recent change occurred on April 22, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
